Pharmacokinetics of tenoxicam in patients with impaired renal function
Horber, F. F. ; Guentert, T. W. ; Weidekamm, E. ; Heizmann, P. ; Descoeudres, C. ; Frey, F. J.
Springer
Published 1986
Springer
Published 1986
| ISSN: |
1432-1041
|
|---|---|
| Keywords: |
tenoxicam ; renal insufficiency ; non-steroidal antiinflammatory agents ; protein binding ; metabolism ; pharmacokinetics
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Chemistry and Pharmacology
Medicine
|
| Notes: |
Summary The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5′OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138±53 µg/ml·h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5′OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5′OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798295568885219330 |
|---|---|
| autor | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. |
| autorsonst | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. |
| book_url | http://dx.doi.org/10.1007/BF00615961 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM202445941 |
| issn | 1432-1041 |
| journal_name | European journal of clinical pharmacology |
| materialart | 1 |
| notes | Summary The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5′OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138±53 µg/ml·h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5′OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5′OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure. |
| package_name | Springer |
| publikationsjahr_anzeige | 1986 |
| publikationsjahr_facette | 1986 |
| publikationsjahr_intervall | 8014:1985-1989 |
| publikationsjahr_sort | 1986 |
| publisher | Springer |
| reference | 29 (1986), S. 697-701 |
| schlagwort | tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics |
| search_space | articles |
| shingle_author_1 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. |
| shingle_author_2 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. |
| shingle_author_3 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. |
| shingle_author_4 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. |
| shingle_catch_all_1 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. Pharmacokinetics of tenoxicam in patients with impaired renal function tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics Summary The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5′OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138±53 µg/ml·h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5′OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5′OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure. 1432-1041 14321041 Springer |
| shingle_catch_all_2 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. Pharmacokinetics of tenoxicam in patients with impaired renal function tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics Summary The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5′OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138±53 µg/ml·h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5′OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5′OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure. 1432-1041 14321041 Springer |
| shingle_catch_all_3 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. Pharmacokinetics of tenoxicam in patients with impaired renal function tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics Summary The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5′OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138±53 µg/ml·h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5′OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5′OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure. 1432-1041 14321041 Springer |
| shingle_catch_all_4 | Horber, F. F. Guentert, T. W. Weidekamm, E. Heizmann, P. Descoeudres, C. Frey, F. J. Pharmacokinetics of tenoxicam in patients with impaired renal function tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics tenoxicam renal insufficiency non-steroidal antiinflammatory agents protein binding metabolism pharmacokinetics Summary The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5′OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138±53 µg/ml·h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5′OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5′OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure. 1432-1041 14321041 Springer |
| shingle_title_1 | Pharmacokinetics of tenoxicam in patients with impaired renal function |
| shingle_title_2 | Pharmacokinetics of tenoxicam in patients with impaired renal function |
| shingle_title_3 | Pharmacokinetics of tenoxicam in patients with impaired renal function |
| shingle_title_4 | Pharmacokinetics of tenoxicam in patients with impaired renal function |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:38:14.804Z |
| titel | Pharmacokinetics of tenoxicam in patients with impaired renal function |
| titel_suche | Pharmacokinetics of tenoxicam in patients with impaired renal function |
| topic | V WW-YZ |
| uid | nat_lic_papers_NLM202445941 |